In a report released today, Ami Fadia from Needham maintained a Buy rating on Alkermes, with a price target of $45.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ami Fadia has given his Buy rating due to a combination of factors, including Alkermes’s ability to largely meet expectations on both earnings and revenue despite modest cost-driven EPS pressure in 4Q25. Management’s 2026 sales outlook, with net revenue guidance centered just below $1.8B, closely matches Street forecasts, supporting confidence in the durability of the company’s commercial portfolio.
In addition, the upcoming Phase 3 start for Alixorexton in 1Q26 provides a catalyst for potential longer‑term growth beyond the current franchise. The outlined CEO transition from Richard Pops to Blair Jackson by August 2026 appears orderly, reducing governance overhang and suggesting strategic continuity, which together underpin Fadia’s constructive stance on the shares.
In another report released on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $45.00 price target.